Allergan said that Restasis is the first prescription eye drop to target the underlying cause of chronic Dry Eye.
Allergan claimed that Restasis helps increase the eye’s natural ability to produce tears, which may be reduced by inflammation due to Dry Eye.
University of Ottawa Eye Institute, The Ottawa Hospital Ophthalmology professor Bruce Jackson said that by increasing tear production, Restasis is the first approved drug that targets the underlying cause of Dry Eye.